Recombinant humanized anti-FB5 antibodies

US5811522A · kind A · utility

Assignee

• LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

• Thomas Paul Wallace · Methlick, GB
• Francis Joseph Carr · Aberdeen, GB
• Wolfgang J. Rettig · Biberach, DE
• Pilar Garin-Chesa · Biberach, DE
• Lloyd J. Old · New York, US

Key dates

• Filing date: May 20, 1996
• Grant date: Sep 22, 1998
• Expiry date: May 20, 2016

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumours. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.